A 300 IR 5-grass pollen sublingual immunotherapy tablet-specific systematic review and meta-analysis confirms its clinical benefits for patients with allergic rhinoconjunctivitis with or without asthma
This product-specific meta-analysis reinforces the evidence of clinical benefits associated with the 300 IR 5-grass SLIT-tablet, suggesting its appropriateness as a therapeutic choice for patients with ARC, irrespective of concurrent asthma, and exhibiting a favorable safety profile.
Authors
- Giorgio Walter Canonica (ORCID: https://orcid.org/0000-0001-8467-2557)
- Danilo Di Bona (ORCID: https://orcid.org/0000-0002-9728-3806)
- Silvano Dragonieri (ORCID: https://orcid.org/0000-0003-1563-6864)
- Michał Ordak (ORCID: https://orcid.org/0000-0001-5652-4397)
- Josiane Cognet-Sicé
- Giovanni Paoletti (ORCID: https://orcid.org/0000-0003-3953-9225)
- Silvia Scurati
Institutions
- University of Foggia (IT)
- Humanitas University (IT)
- Stallergenes Greer (France) (FR)
Publication Details
- Journal
- World Allergy Organization Journal
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1016/j.waojou.2024.100985
- Citations
- 4
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- article
- Field-Weighted Citation Impact
- 1.53